Observational studyRenal failure2021
Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin.
Observational study in Renal failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Hemoglobin and human longevity: integrating oxygen transport, redox biology, and aging pathways - a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Analysis of red blood cell lifespan and associated influencing factors in anemic dialysis patients.Renal failure · 2025Article
- Erythrocyte lifespan for predicting moderate and severe anemia in advanced gastric cancer patients post-anti-tumor therapeutics: a prospective study.BMC cancer · 2025Article
- Hypoxia-inducible factor-prolyl hydroxylase inhibitors in treatment of anemia with chronic disease.Chinese medical journal · 2025Review
- Review
- Detection and clinical application of red blood cell survival.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Review
- Excessive Erythrophagocytosis Accounts for Systemic Inflammation in Chronic Kidney Disease.Journal of inflammation research · 2024Article
- Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations.Clinical kidney journal · 2024Article
- Effect of roxadustat on red blood cell lifespan in patients with long-term haemodialysis: a single-centre, prospective, single-arm study.Clinical kidney journal · 2023Article
- Article
- Plasma phospholipids profiling changes were associated with the therapeutic response to Roxadustat in peritoneal dialysis patients.Frontiers in physiology · 2023Article
- Efficacy of daprodustat on anemia in hemodialysis patients with sustained inflammation: a case report.CEN case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionA significant decrease in red blood cell (RBC) survival has been observed in patients with renal failure, which is supposed to contribute to renal anemia. The aim of this observational study was to determine RBC survival in hemodialysis (HD) patients treated with roxadustat or recombinant human erythropoietin (rhuEPO) compared with healthy persons.
methodsRBC lifespan was measured by Levitt's CO breath test with newly developed automatic instrument ELS Tester.
resultsA total of 102 patients receiving long-term HD from two independent dialysis centers enrolled in the study, of whom 62 were treated with rhuEPO and 40 were on roxadustat therapy. A total of 25 healthy participants were recruited to match HD participants according to age and sex. Median RBC survival times in rhuEPO, roxadustat, and control groups were 65.0 (25th-75th percentile, 49.5-77.3), 75.5 (25th-75th percentile, 57.3-99.3), and 108.0 (25th-75th percentile, 89.0-141.5) d, respectively. Patients treated with roxadustat had significantly longer RBC survival time than patients treated with rhuEPO (
conclusionsHD patients treated with roxadustat had significantly longer RBC survival time than patients treated with rhuEPO, large prospective studies with long-term follow-up are warranted to verify the results in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.